Functional and morphologic studies of fibrin formation in the presence of a variety of cancer chemotherapeutic agents in vitro showed that some of these drugs cause fibrinolysis, inactivation of fibrin-stabilizing factor (FSF), or a combination of both. T h e drugs with most potent activity are 5-[3,3-bis(2-chloroethyl)-l-triazeno]imidazole-4-carboxamide (TIC mustard), 5-fluorouracil, nitrogen mustard, adriamycin, and daunomycin. These changes were dose related.
Introduction
have been reported with the administration of nitroIn a variety of animal tumor systems [5] [6] [7] 9 , 161, successful implantation of metastases is related to fibrin formation and platelet aggregation around the embolized tumor cells. Inhibitors of fibrin formation (heparin [7] and coumadin [14] ), inhibitors of platelet aggregation (aspirin [l I]), inhibitors of fibrin stabilization (poly-L-lysine [12] ), accelerators of fibrinolysis (plasmin [3] ), and inducers of thrombocytopenia (neuraminidase [8] ) have been reported to decrease the numbers of metastases in these tumor systems. Conversely, gen mustard- [6] and triethylenethiophosphoramide [lo] . It has generally been assumed that the role of adjuvant chemotherapy at the time of tumor manipulation is to reduce metastases by interfering with cell multiplication. Cliffton and Agostino [4] suggested that the protective effect might involve action of the coagulation system. It is the purpose of this paper to report in vitro studies of the influence of a variety of cancer chemotherapeutic agents on fibrin formation and stabilization.
9 parts whole blood to 1 part 3.8% sodium citrate. After centrifugation at 4' for 15 min at 1,500 rpm, platelet-poor plasma was separated, pooled, and frozen i n small aliquots in siliconized tubes. Aliquots were thawed just before use.
Chemotherapeutic Agents
T h e following drugs were dissolved with their appropriate solvent for intravenous administration: vincristine (Oncovin) [17] , vinblastine (Velban) [17] , cytosine arabinoside (Cytosar) [18] , actinomycin D (Cosmogen) [19] , methotrexate [20] , cyclophosphamide (Cytoxan) [2 11 , nitrogen mustard (Mustargen) [I 81, daunorubricin [22] , adriamycin [22] , L-asparaginase 1191, 5-fluorouracil [23] , and T I C mustard [24] . Further dilutions were made with sterile solvent just before use in testing. Table I lists the agent, its solvent, and the concentration of a 111 dilution. Test dilutions were chosen to approximate high concentrations anticipated with perfusion rather than plasma levels after infusion.
Serial Thrombin T i m e
Bovine thrombin [25] was dissolved with normal NaCl solution to give a concentration of 10 U/ml and was stored frozen in siliconized tubes until just before use. Thrombin solution was kept in a melting ice bath during use in testing.
Plasma (0.1 ml) and drug dilution (0.1 ml) were placed in Fibrometer [26] cups on a heating block. Thrombin time was determined at 0-and 60-min incubation at 37" by the addition of 0.1 ml thrombin solution. All determinations were performed in duplicate. Control tests were performed substituting the appropriate solvent for the drug. Drugs associated 
Urea Solubility
Equal volumes of normal plasma and 1 / 1 drug dilution (see Table I ) were incubated at 37" for 60 min i n glass tubes in a water bath. Clots were formed by recalcification of 1 ml mixture with 0.1 ml 0.25 M CaCI,. T h e clots were suspended in a solution of 5 M urea and observed during the next 4-8 h r for dissolution. Saline and the appropriate drug solvents were substituted for drug in control determinations. Abnormal studies were repeated with the addition of 6-ACA to the drug solvent before mixing with plasma.
pH Studies
Equal parts of plasma were mixed with a 111 drug dilution and allowed to come to room temperature before the p H was determined by a Digicord p H meter [27] . Samples that were very alkaline were acidified drop-wise with 0.1 N HC1. Acid samples were alkalinized with 0.1 N NaOH. I n studies with 5-fluorouracil it was necessary to acidify with 1 N HCl in order to accomplish decremental p H changes without excessive dilution. Thrombin time was performed as above on samples for each p H unit change of 0.1. Plasma-drug samples at p H 7.6 were recalcified with 0.025 M CaC1,. Fibrin thus formed was placed in 5 M urea and observed for solubility.
Electrical Resistance Studies
Two milliliters of plasma were activated by mixing in a clean glass tube (12 by 75 mm) for 3 min. Twotenths milliliter of a 112 drug dilution and 0.2 ml 0.25 M CaCI, were added sequentially with thorough mixing after each addition. T h e plasma was then placed in an aluminum incubation cell at 37". T h e polymerization of the resulting fibrin was monitored by measuring the DC resistance of the plasma with an electrometer [28] . Optical density was monitored simultaneously. A pair of spherical microelectrodes melted and shaped from gold wire, 1.5 cm in length by 0.008 inch i n diameter [29] , were suspended i n the tube of plasma with a pair of plain glass capillary tubes [30] . "Incubated" studies were performed by addition of drug to plasma 1 h r at 39" before glass activation and recalcification.
Electron iMicroscopy (Figs. 1 and 2 )
Normal plasma was mixed with a 112 drug dilution i n the ratio of 2 parts plasma to 1 part drug. All samples except for HN, and T I C mustard were incubated at 37" for 60 min. After incubation, 2 ml drugplasma sample were activated in glass for 3 min and then recalcified by the addition of 0.2 ml 0.25 M CaC1,. T h e plasma was pipetted into a 19 cm length of silicon rubber tubing with an internal diameter of 3 mm. T h e plasma was allowed to flow over the surface of a carbon plastic film mounted on an electron microscope grid on a substrate holder. Both ends of the tubing were inserted into the substrate holder to form a closed loop 131. T h e circular tube was then secured on a turntable and rotated at 15 rpm until a fibrin clot formed in the moving plasma column. T h e specimens were removed from the substrate holder and fixed in 10% formalin for 12 hours.
In preparation for electron microscopy, the samples were stained for 2 min with uranyl acetate, washed in distilled water, and air-dried. T h e microscopy was performed on a JEM-6A transmission electron microscope at 100 kV.
Results

Serial T h r o m b i n T i m e
On the basis of serial thrombin times of mixtures of chemotherapeutic agents with plasma, drugs could be divided into three classes: class I, no influence on thrombin time; class 11, abnormal incubated thrombin time corrected by premixture with cACA; class III, markedly abnormal thrombin time with and without incubation; no correction by premixture of incubated specimen with E-ACA. Table I1 summarizes the thrombin times for each drug at three dilutions. Thrombin times that were abnormal were less so as the concentration of drug was alcohol, normal saline without preservative, distilled Stepwise correction of p H towards 7.4 for classes I1 and I11 drugs reduced the magnitude of the thrombin time abnormality (Table IV) bin times were observed with class I agents at similar extremes of pH.
Urea Solubility
Plasma containing normal saline without preservative, distilled water without preservative, or normal saline with benzyl alcohol resisted solubility in 5 M urea during the 48 h r of observation. Plasma which contained 0.01 N HC1 produced recalcified clots that dissolved in less than 24 hr in 5 M urea (Table 111) .
Four classes of agents could be discerned by the pattern of urea solubility. These classes corresponded strictly to those constructed on the basis of thrombin times except for a subdivision among the agents without influence on serial thrombin time (class I). Subclass A, exemplified by vincristine, vinblastine, actinomycin D, and cytosine arabinoside, showed normal resistance to solubility in 5 M urea. Subclass B agents, daunorubricin, adriamycin, and L-asparaginase, although without influence on the thrombin time, did influence urea solubility. This solubility was not influenced by prior incubation with E-ACA. Adjustment of the p H to 7.6 before recalcification did prevent dissolution of clots formed in plasma containing L-asparaginase. Clots formed in the presence of daunorubricin and adriamycin remained soluble in 5 M urea despite adjustment of the p H to 7.6.
Class ZZ agents such as methotrexate, cyclophosphamide, and HN, were associated with progressive prolongation of thrombin time and increased urea solubility. Prior incubation with E-ACA prevented urea solubility. Adjustment of p H to 7.6 did not prevent urea solubility in the absence of E-ACA.
T h e protective effect of incubation with cACA on urea solubility was not seen with class ZZZ agents. Adjustment of p H to 7.6 for 5-fluorouracil did not prevent urea solubility.
Electrical Resistance Studies
During clot formation, a sigmoid curve with two inflections portrays the changes in electrical resistance in normal plasma. At the recalcification time, the electric resistance of the plasma increases markedly, seen by the first inflection ( # I ) in the curve (Fig. 3) . Normally, the electrical resistance again shows another sharp increase displaying a broader inflection (g2).
Abnormal curves were observed for all drugs in classes I-B, ZZ, and ZZZ. T h e values for the time after recalcification for the inscription of the second inflection are summarized i n Table V. Delay of the second inflection corresponded to solubility of fibrin in urea (Table VI) . 
Electron Microscopy
Three types of abnormalities of fibrin formation were seen by transmission electron microscopy. T h e pattern for each drug is summarized in Table VII . Sparse fibrin formation, frayed rope appearance of the strands, and loss of cross-striations were prominent in phologic studies of the third stage of coagulation sugclass I-B, IZ, and ZZZ agents.
gest that several mechanisms are operative. Agents grouped together as class 1-B do not alter the Discussion rate at which fibrin is formed although abnormal fibrin was visible by electron microscopy. Abnormal sol-I t is apparent from these data that high concentrations ubility in 5 urea uncorrected by an antifibrinolytic of some chemotherapeutic agents impede stable fibrin agent and delayed inscription of the second formation i n vitro. Differences in functional and morof the electric resistance curve were observed. These -: normal; + : abnormal; f : slightly abnormal. solubility was restored for plasma containing L-asparaginase when the p H was adjusted to 7.6. Loewy [13] has observed less activity of FSF at extremes of p H and optimal activity at 7.6. Adjustment of p H of plasma containing daunomycin and adriamycin to 7.6 did not prevent urea solubility, which suggests that, for these agents, the drug rather than the p H was responsible for loss of FSF activity.
5-[3,3-Bis(2-chloroethyl) -1 -triazeno]imidazole4-carboxamide
T h e abnormalities seen with class ZZ drugs are consistent with increased fibrinolysis. Incubation with E-ACA corrected thrombin time prolongation and urea solubility. Since FSF can serve as a substrate for fibrinolysins [ll], it is not surprising to find a deficit of FSF activity.
Class IZZ agents, exemplified by 5-fluorouracil and T I C mustard, produced profound defects in all test systems. Although each represents an extreme of p H (8.0 and 3.7, respectively), neutralization of the plasma containing 5-fluorouracil to 7.4 only partially corrected the thrombin time abnormality. Similar studies were not possible for T I C mustard, because it is insoluble at more alkaline p H [Z] . T h e properties of its solvent and its failure to remain soluble under less acid conditions prevent us from distinguishing from solvent and solute as cause for defective fibrin formation.
T h e relevance of these findings to clinical situations remains to be proven. Studies of blood from patients who receive these agents are necessary to determine whether fibrin formation is impeded in vivo.
Summary
When a variety of chemotherapeutic agents reconstituted as for intravenous administration were mixed with normal plasma, defective fibrin was formed. Mechanisms varied and included increased fibrinolysis and inactivation of fibrin-stabilizing factor. In one instance the abnormality was related to the pH of the reconstituted drug rather than specific action of the agent.
